EGFR GENE HEAN9 MUTATION

Lung cancer has become the leading cause of cancer deaths worldwide, seriously threatening human health. Non-small cell lung cancer accounts for about 80% of lung cancer patients. EGFR is currently the most important molecular target for the treatment of non-small cell lung cancer. Fosforir saka EGFR bisa ningkatake pertumbuhan sel tumor, bedane, invasi, metastasis, anti-apoptosis, lan ningkatake tumor angiogenesis. EGFR inhibitor kinase (TKI) bisa ngalangi dalan signaling egfr kanthi nyandhet autophratelat EGFR, saéngga promosi apososis sel tumor, lan sapiturute, supaya bisa nggayuh terapi target target. Akeh panaliten sing nuduhake manawa khasiat terapi EGFR-TKI rapet karo status mutasi mutasi, lan bisa nyandhet kanthi wutah sel tumor kanthi mutasi gen. The EGFR gene is located on the short arm of chromosome 7 (7p12), with a full length of 200Kb and consists of 28 exons. Wilayah mutasi utamane ing exons 18 nganti 21, Codons 746 nganti 753 mutasi pambusakan ing 195% lan mutasi l858r ing sekitar 40% nganti 45%. Pedoman NCCN kanggo diagnosis lan perawatan kanker lung cell cilik sing ora jelas nyatakake yen tes mutasi mutasi dibutuhake sadurunge administrasi EGFR-TKI. Kit uji iki digunakake kanggo nuntun administrasi epidermis wutah faktor tylrosine kinase inhibitor (egfr-tki) obat-obatan, lan menehi basis obat-obatan sing ora cilik kanggo pasien sing ora duwe paru-paru cell cilik. This kit is only used for the detection of common mutations in the EGFR gene in patients with non-small cell lung cancer. Asil tes mung kanggo referensi klinis mung lan ora bisa digunakake minangka dhasar kanggo perawatan pasien individu. Klinik kudu nimbang kahanan pasien, indikasi narkoba, lan perawatan reaksi lan indiktor tes laboratorium lan faktor liyane digunakake kanggo ngadili asil asil tes.